| Identification | Back Directory | [Name]
TAK-659 | [CAS]
1312691-33-0 | [Synonyms]
TAK-659
Mivavotinib
Tak-659 free base
MIVAVOTINIB;TAK 659;TAK659
TAK-659 free base(Mivavotinib)
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
3H-Pyrrolo[3,4-c]pyridin-3-one, 6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C17H21FN6O | [MDL Number]
MFCD30829411 | [MOL File]
1312691-33-0.mol | [Molecular Weight]
344.39 |
| Chemical Properties | Back Directory | [Boiling point ]
661.7±55.0 °C(Predicted) | [density ]
1.58±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
10.90±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
Mivavotinib is employed in the discovery of Lanraplenib, a tyrosine kinase inhibitor for autoimmune diseases. | [in vivo]
TAK-659 (100 mg/kg/day; p.o.; for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments[4].
TAK-659 treatment kills tumor cells, but not host cells within the spleen and tumors[4].
TAK-659 treatment abrogates metastasis of tumor cells into bone marrow[4].
| Animal Model: | LMP2A/MYC double transgenic mice[4] | | Dosage: | 100 mg/kg/day | | Administration: | Oral gavage; for 10 days | | Result: | Inhibited LMP2A-induced tumor cell survival in vivo. |
| [storage]
Store at -20°C |
|
| Company Name: |
Twochem Co.Ltd
|
| Tel: |
021-021-58111628 15800915896 |
| Website: |
www.twochem.com |
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 19945035818 |
| Website: |
http://www.topule.com/ |
|